Chronic fibrotic liver diseases such as viral hepatitis eventually develop liver cirrhosis, which
causes occurrence of hepatocellular carcinoma (HCC). Given the limited therapeutic efficacy …

Abstract Purpose and Design Intra-arterial therapies for unresectable hepatocellular
carcinoma (HCC) consist of a catheter-based group of treatments where therapeutic and/or …

Background Effective adjuvant treatment after hepatectomy for hepatocellular carcinoma
(HCC) is an important area of research. Radioactive iodine (131 I)-labelled metuximab is a …

Background Postoperative recurrence of hepatocellular carcinoma (HCC) is a major
problem after surgical resection. To date, adjuvant chemotherapy or other adjuvant …

Abstract Yttrium-90 (Y90) radioembolization is an emerging strategy to treat liver
malignancies, and clinical data supporting its use have accumulated in recent years. Y90 …

Hepatocellular carcinoma (HCC) is becoming an important public health concern. Current
therapeutic options are limited and new treatments are therefore being developed. The intra …

Background The recurrence of hepatocellular carcinoma is still high even after surgery. Two
general recurrence patterns occur: intrahepatic metastasis (IM) and multicentric …

Background Curative resection for hepatocellular carcinoma (HCC) has an 80% recurrence
at 5 years. Survival could be prolonged with adjuvant iodine 131 lipiodol. This systematic …

Background Internal irradiation with iodine-131 (131 I)-labeled Lipiodol is one of the
currently available forms of palliative therapy for patients with advanced hepatocellular …

The recurrence rate of hepatocellular carcinoma (HCC) after potentially curative hepatic
resection (HR) is very high. Many clinical trials have explored the efficacy of several …